Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Synta Pharmaceuticals Corp. Clear all
Completed Phase 1Phase 2 Interventional Results available

SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

NCT02008877
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
Interventions
ganetespib, Sirolimus
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

NCT00088101
View directory record Official record
Conditions
Hematological Malignancies, Leukemia, Lymphoma, Metastatic or Unresectable Solid Tumors
Interventions
STA-5312
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
8
States / cities
Pomona, California • Jacksonville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

NCT00964873
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Blast-phase Chronic Myelogenous Leukemia, AML, ALL, CML
Interventions
STA-9090 (ganetespib)
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Tampa, Florida • Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional

STA-5326 in Crohn's Disease Patients

NCT00088062
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
18
States / cities
Tucson, Arizona • Anaheim, California • North Miami Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors

NCT01183364
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
STA-9090 (ganetespib) with Docetaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer

NCT01554969
View directory record Official record
Conditions
Rectal Cancer
Interventions
capecitabine + ganetespib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

NCT00687934
View directory record Official record
Conditions
Solid Tumors
Interventions
STA-9090
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
25 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Santa Monica, California • Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

NCT00084214
View directory record Official record
Conditions
Melanoma
Interventions
STA-4783, Paclitaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
28
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

NCT01031225
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
STA 9090
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
21
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT01562015
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ganetespib
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Tampa, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 2, 2026, 4:08 AM EDT
Terminated Phase 2Phase 3 Interventional

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

NCT01348126
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
Interventions
Docetaxel, Combination of ganetespib and docetaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Tucson, Arizona • Santa Monica, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Clinical and Translational Study of STA-9090

NCT01111838
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
STA-9090
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

NCT00088088
View directory record Official record
Conditions
Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, STA 4783
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
19
States / cities
Jonesboro, Arkansas • Pomona, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

NCT01273896
View directory record Official record
Conditions
Breast Cancer
Interventions
STA-9090
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

NCT01039519
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
Ganetespib
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 2, 2026, 4:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

NCT02261805
View directory record Official record
Conditions
Cancer, Small Cell Lung Cancer
Interventions
Ganetespib, Doxorubicin
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

STA-9090 in Patients With Advanced Hepatocellular Cancer

NCT01665937
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
STA-9090
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 2, 2026, 4:08 AM EDT
Terminated Phase 1 Interventional

Ganetespib Window of Opportunity Study in Head and Neck Cancers

NCT02334319
View directory record Official record
Conditions
Stage I Hypopharyngeal Squamous Cell Carcinoma, Stage I Laryngeal Squamous Cell Carcinoma, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Hypopharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma
Interventions
Ganetespib, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
Emory University
Other
Eligibility
19 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 2, 2026, 4:08 AM EDT
Terminated Phase 3 Interventional

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

NCT00522834
View directory record Official record
Conditions
Melanoma
Interventions
Elesclomol (STA-4783), Paclitaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

NCT00138840
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326 mesylate
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
31
States / cities
Little Rock, Arkansas • Anaheim, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT01485835
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ganetespib, Bortezomib, Dexamethasone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Denver, Colorado • Atlanta, Georgia • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

NCT01167114
View directory record Official record
Conditions
Esophagogastric Cancer
Interventions
STA-9090
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

NCT00808418
View directory record Official record
Conditions
Prostate Cancer
Interventions
Elesclomol Sodium, Docetaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Fountain Valley, California • Rochester, Maryland • Bismarck, North Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

NCT00234741
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326 mesylate
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 2, 2026, 4:08 AM EDT